RYZ401 Phase 2 Study Initiated for Solid Tumors with SSTR Expression
A Phase 2 study of RYZ401 is underway to establish the recommended dose and assess safety and efficacy in solid tumors expressing SSTRs.
Asset / Drug
Drug and asset intelligence for RYZ401 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.